Cargando…

Successful perioperative management of a patient with erythropoietin-producing uterine myoma

BACKGROUND: Erythropoietin-producing uterine myoma can cause various complications such as arterial or venous thrombosis and bleeding. Therefore, caution is required in the anesthetic management of affected patients. CASE PRESENTATION: A 57-year-old female was suspected to have an erythropoietin-pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Masato, Akatsu, Masahiko, Fujita, Yoshihisa, Nishikawa, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967353/
https://www.ncbi.nlm.nih.gov/pubmed/32025892
http://dx.doi.org/10.1186/s40981-018-0185-y
_version_ 1783488933907136512
author Kobayashi, Masato
Akatsu, Masahiko
Fujita, Yoshihisa
Nishikawa, Koichi
author_facet Kobayashi, Masato
Akatsu, Masahiko
Fujita, Yoshihisa
Nishikawa, Koichi
author_sort Kobayashi, Masato
collection PubMed
description BACKGROUND: Erythropoietin-producing uterine myoma can cause various complications such as arterial or venous thrombosis and bleeding. Therefore, caution is required in the anesthetic management of affected patients. CASE PRESENTATION: A 57-year-old female was suspected to have an erythropoietin-producing uterine myoma and was scheduled to undergo an abdominal total hysterectomy and bilateral salpingo-oophorectomy. Preoperative levels of hemoglobin and erythropoietin were 21.9 g/dl (normal 11.5–15 g/dl) and 23.2 IU/ml (normal 4.2–23.7 IU/ml), respectively. Preoperative phlebotomy and isovolemic hemodilution were performed to prevent arterial and venous thrombosis, following previous evidence that a hemoglobin level < 16 g/dl reduces the occurrence of polycythemia vera-related complications. Fondaparinux 2.5 mg was subcutaneously injected once daily after the operation, resulting in a good perioperative course without major complications. CONCLUSION: Herein, we have described a successful perioperative management of a patient with erythropoietin-producing uterine myoma. Our findings in this case suggest that this combination of antithrombotic therapies can facilitate anesthetic management of patients with this disease.
format Online
Article
Text
id pubmed-6967353
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-69673532020-02-04 Successful perioperative management of a patient with erythropoietin-producing uterine myoma Kobayashi, Masato Akatsu, Masahiko Fujita, Yoshihisa Nishikawa, Koichi JA Clin Rep Case Report BACKGROUND: Erythropoietin-producing uterine myoma can cause various complications such as arterial or venous thrombosis and bleeding. Therefore, caution is required in the anesthetic management of affected patients. CASE PRESENTATION: A 57-year-old female was suspected to have an erythropoietin-producing uterine myoma and was scheduled to undergo an abdominal total hysterectomy and bilateral salpingo-oophorectomy. Preoperative levels of hemoglobin and erythropoietin were 21.9 g/dl (normal 11.5–15 g/dl) and 23.2 IU/ml (normal 4.2–23.7 IU/ml), respectively. Preoperative phlebotomy and isovolemic hemodilution were performed to prevent arterial and venous thrombosis, following previous evidence that a hemoglobin level < 16 g/dl reduces the occurrence of polycythemia vera-related complications. Fondaparinux 2.5 mg was subcutaneously injected once daily after the operation, resulting in a good perioperative course without major complications. CONCLUSION: Herein, we have described a successful perioperative management of a patient with erythropoietin-producing uterine myoma. Our findings in this case suggest that this combination of antithrombotic therapies can facilitate anesthetic management of patients with this disease. Springer Berlin Heidelberg 2018-06-18 /pmc/articles/PMC6967353/ /pubmed/32025892 http://dx.doi.org/10.1186/s40981-018-0185-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Kobayashi, Masato
Akatsu, Masahiko
Fujita, Yoshihisa
Nishikawa, Koichi
Successful perioperative management of a patient with erythropoietin-producing uterine myoma
title Successful perioperative management of a patient with erythropoietin-producing uterine myoma
title_full Successful perioperative management of a patient with erythropoietin-producing uterine myoma
title_fullStr Successful perioperative management of a patient with erythropoietin-producing uterine myoma
title_full_unstemmed Successful perioperative management of a patient with erythropoietin-producing uterine myoma
title_short Successful perioperative management of a patient with erythropoietin-producing uterine myoma
title_sort successful perioperative management of a patient with erythropoietin-producing uterine myoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967353/
https://www.ncbi.nlm.nih.gov/pubmed/32025892
http://dx.doi.org/10.1186/s40981-018-0185-y
work_keys_str_mv AT kobayashimasato successfulperioperativemanagementofapatientwitherythropoietinproducinguterinemyoma
AT akatsumasahiko successfulperioperativemanagementofapatientwitherythropoietinproducinguterinemyoma
AT fujitayoshihisa successfulperioperativemanagementofapatientwitherythropoietinproducinguterinemyoma
AT nishikawakoichi successfulperioperativemanagementofapatientwitherythropoietinproducinguterinemyoma